Revolutionising automated digital epilepsy diagnosis quickly and accurately. Created by an expert in the mathematical modelling of epilepsy. Tried and tested by neurologists.

Neuronostics is targeting the $180bn epilepsy cost and treatment market, with long-term expansion into the $2tr neurological illness cost market.

Key partner Stratus (the leading US EEG services provider) offers a turnkey route to market and removes the need for Neuronostics to have a US salesforce by providing nationwide coverage via 800+ hospital systems to 30,000 annual tests. BioEP is embedded in their platform and already being used in the UK.

Early sales generated across the UK via the NHS – ongoing service evaluations and clinical trials with 20+ NHS Trusts. The focus is on the UK through 2026 with US expansion in 2027.

Neuronostics has raised c£4.9m in equity and £850k in grant funding to date, plus won a $125k prize. This has been used to build the product, bring it to market and secure validation from medical professionals and software and data analysis providers in the supply chain.

The Company is currently raising up to £3.5m (EIS qualifying and expected to 
achieve Knowledge Intensive Company (KIC) status). Of which £2.6m equity 
funding has already been invested by VCs (lead by Empirical Ventures and 
including FSE Group) at a £6.4m pre-money valuation, plus a £400k Innovate 
UK grant.

The funding will be used for key sales hires, to expand in-house technology 
capability (already there is no reliance on outsourced development), including 
development of their multiple versions of BioEP to accelerate growth.

Your VC has secured an allocation of up to £264k of the round for its investors, benefiting from the same share price as at the beginning of the round before £3m had been raised.